POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical trial evaluating investigational therapy IGC-AD1 for agitation in Alzheimer’s dementia, with the addition of Colombia’s Grupo de Neurociencias de Antioquia (GNA) as a new research site. The move extends the study’s international footprint and strengthens enrollment capacity within a region globally recognized for genetically linked Alzheimer’s populations, marking a strategic milestone in the program’s clinical execution.
Science Significance
The CALMA study is a randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate the safety and efficacy of IGC-AD1 in managing agitation associated with Alzheimer’s dementia. The investigational therapy is a cannabinoid-based formulation engineered to modulate neuropsychiatric symptoms through neuroinflammatory and neurotransmitter pathways. Expansion into GNA introduces access to longitudinal Alzheimer’s cohorts with genetically predisposed disease progression, offering valuable biomarker, cognitive, and behavioral datasets. This population diversity enhances statistical power and supports deeper analysis of treatment response across hereditary and sporadic Alzheimer’s subtypes, strengthening translational neuroscience insights.
Regulatory Significance
International site expansion reflects continued regulatory and ethics alignment under Good Clinical Practice frameworks. Activation of the Colombia research center required local regulatory approvals, institutional review board oversight, and investigational product compliance clearances. The trial has reached approximately 70% of targeted enrollment, positioning database lock and topline data readout as the next major regulatory milestones. Multinational trial conduct also supports future global filing strategies by generating geographically diverse safety and efficacy data acceptable to multiple health authorities.
Business Significance
Advertisement
The expansion reinforces IGC Pharma’s operational scalability and late-stage clinical development readiness. The CALMA network now spans 23 active sites across 26 locations in North and South America, enhancing recruitment velocity and trial execution resilience. Broader geographic participation supports investor confidence and partnership attractiveness, particularly as Alzheimer’s therapeutics remain a high-value pharmaceutical segment. The company’s integration of artificial intelligence for patient targeting and trial optimization further differentiates its development model and may improve clinical efficiency, cost control, and outcome predictability.
Patients’ Significance
Agitation is among the most burdensome neuropsychiatric symptoms of Alzheimer’s disease, significantly impacting patient safety, caregiver stress, and institutionalization risk. Existing treatment options remain limited and are often associated with tolerability challenges. By expanding trial access into Latin America, the study enables participation from underrepresented patient populations while accelerating evaluation of a therapy aimed at improving behavioral stability and quality of life. Inclusion of genetically linked Alzheimer’s cohorts may also provide insights into earlier intervention opportunities for high-risk families.
Policy Significance
Cross-border Alzheimer’s research expansion highlights the growing importance of global collaboration in neurodegenerative disease innovation. Regions with concentrated hereditary Alzheimer’s populations offer unique scientific and public health value, informing prevention strategies and therapeutic development. Trial expansion into such geographies supports equitable research representation while strengthening healthcare infrastructure, investigator training, and clinical research capacity. As dementia prevalence rises worldwide, multinational trial models will be essential for generating inclusive evidence to inform treatment guidelines and reimbursement policy.
With enrollment nearing completion and international site activation accelerating, the CALMA trial advances toward a pivotal data inflection point in Alzheimer’s agitation research. The integration of genetically enriched populations, AI-enabled analytics, and cannabinoid-based neuropsychiatric modulation underscores a multifaceted innovation strategy. Upcoming topline results will be closely watched to determine the therapy’s potential role in addressing one of dementia care’s most challenging behavioral manifestations.
Source: IGC Pharma press release
